



June 30, 2023

Lumos Diagnostics, Inc.  
Sue Hibbeln  
VP, Quality and Regulatory Affairs  
2724 Loker Avenue  
Carlsbad, California 92010

Re: K230917

Trade/Device Name: FebriDx Bacterial / Non-bacterial Point of Care Assay

Regulation Number: 21 CFR 866.3230

Regulation Name: Device To Detect And Measure Non-Microbial Analytes To Aid In The Detection  
And Identification Of Localized Human Infections

Regulatory Class: Class II

Product Code: QXA

Dated: March 31, 2023

Received: April 3, 2023

Dear Sue Hibbeln:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

  
**Noel J. Gerald -S**

Noel J. Gerald, Ph.D.  
Branch Chief  
Bacterial Respiratory and Medical Countermeasures Branch  
Division of Microbiology Devices  
OHT7: Office of In Vitro Diagnostics  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)  
K230917

Device Name

FebriDx Bacterial / Non-bacterial Point-of-Care Assay  
FebriDx External Controls

Indications for Use (Describe)

The FebriDx Bacterial / Non-bacterial Point-of-Care Assay is a qualitative visually read rapid immunoassay for the detection of human host response proteins, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from fingerstick blood. FebriDx is indicated for use in patients aged 12-64 who present to urgent care or emergency care settings for evaluation of acute respiratory infection who have had symptoms for less than 7 days and within 3 days of fever onset.

FebriDx test results are intended to be used in conjunction with other clinical and diagnostic findings as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology. The assessment of whether a bacterial infection is present should always be based on consideration of all available information, and not based solely on the FebriDx test results. FebriDx test results are not intended to identify a specific pathogen or the severity of infection.

FebriDx External Controls are used in the FebriDx Test as assayed quality control samples to assess the performance and reliability of the FebriDx Test.

Special conditions for use statement(s):

- For in vitro diagnostic use
- For prescription use only

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
[PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov)

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*

## 008\_510(k) Summary

### 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

**A. 510(k) Number:** K230917

**B. Applicant:**

Lumos Diagnostics, Inc.  
2724 Loker Avenue W  
Carlsbad, CA 92010

Contact: Sue Hibbeln, MS, RAC

Telephone: 941.867.6150

Email: Sue.Hibbeln@LumosDiagnostics.com

Date Submitted: April 3, 2023

**C. Proprietary and Established Names:** FebriDx® Bacterial / Non-bacterial Point-of-Care Assay, FebriDx® External Controls

**D. Purpose for Submission:** To obtain a substantial equivalence determination for the FebriDx® device.

**E. Measurand:** Dual biomarkers: Myxovirus resistance protein A (MxA) and C-reactive protein (CRP)

**F. Type of Test:** Lateral flow qualitative immunoassay

**G. Regulatory Information:**

1. **Regulation section:** 21 CFR 866.3230

2. **Classification:** Class II

3. **Product code(s):** QXA

4. **Panel:** MI – Microbiology

**H. Intended Use / Indications for Use:**

The FebriDx® Bacterial/Non-Bacterial Point-of-Care Assay is a qualitative visually read rapid immunoassay for the detection of human host response proteins, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from fingerstick blood. FebriDx is indicated for use in patients aged 12-64 who present to urgent care or emergency

care settings for evaluation of acute respiratory infection who have had symptoms for less than 7 days and within 3 days of fever onset.

FebriDx test results are intended to be used in conjunction with other clinical and diagnostic findings as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology. The assessment of whether a bacterial infection is present should always be based on consideration of all available information, and not based solely on the FebriDx test results. FebriDx test results are not intended to identify a specific pathogen or the severity of infection.

FebriDx External Controls:

FebriDx External Controls are used in the FebriDx Test as assayed quality control samples to assess the performance and reliability of the FebriDx Test.

**Special conditions for use statement(s):**

- For *in vitro* diagnostic use
- For prescription use only

**I. Device Description:**

FebriDx Test:

FebriDx is a rapid lateral flow immunoassay for the visual, qualitative, *in vitro* detection of elevated levels of host response proteins, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), directly from fingerstick blood to aid in the evaluation of acute respiratory infections. The single-use, disposable FebriDx test is an all-in-one integrated platform that includes a lateral flow test strip, a built-in retractable safety lancet, blood collection and transfer tube and buffer delivery system. The FebriDx test produces a visual-read qualitative result. Operators interpret the test and can visually see whether the infection may be due to a bacterial infection or other non-bacterial etiology.

**FebriDx External Controls:**

FebriDx External Controls to monitor performance and reliability of the FebriDx test are sold separately. FebriDx External Controls are a two-vial set with one negative buffer and one positive control containing recombinant CRP and MxA.

**J. Test Principle:**

Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) are non-microbial proteins produced by the innate host response (e.g., interferons, interleukins, and the Complement System) in response to infection. The FebriDx test includes a built-in sample collection and transfer tube and detects the presence of MxA and CRP in fingerstick blood specimens using lateral flow technology. A sample of the fingerstick blood is added to the lateral flow test device; followed by a running buffer that provides sufficient volume to activate the test. The running buffer contains leukocyte membrane lysing agents that release intracellular MxA to allow subsequent detection. The first pad in the device filters out the cellular material as well as intact red-blood cells. The filtered sample then contacts a pad that contains the reagents to adjust pH and prevent non-specific binding. Prior to reaching the test strip, free MxA and CRP migrate through a dried formulation of latex beads that have been further conjugated to antibodies specific for binding a particular analyte (MxA or CRP). As the Analyte-Antibody-Bead complex continues to migrate across a porous nitrocellulose membrane, it can interact with one of three capture antibodies that are immobilized on the surface at distinct line positions, including the control line to verify that the device flowed properly. A black line present in the result window indicates a positive result (bacterial) and a red line in the result window or the absence of a line in the result window indicates a non-bacterial etiology, i.e., negative for bacterial infection. FebriDx® simultaneously detects MxA at the medical decision point of approximately 40 ng/mL and CRP of approximately 20 mg/L serum equivalent.

**K. Substantial Equivalence Information:**

- 1. Predicate Device Name:**  
Synovasure Alpha Defensin Lateral Flow Test Kit
- 2. Predicate Number:**  
DEN180032
- 3. Comparison with Predicate:**

*Table 1. Comparison of FebriDx and Predicate Device*

	<b>DEN180032</b> Synovasure Alpha Defensin Lateral Flow Test Kit	<b>K230917</b> FebriDx® Bacterial/Non-Bacterial Point-of-Care Assay
<b>Manufacturer</b>	CD Diagnostics	Lumos Diagnostics, Inc
<b>Intended Use Indications for Use</b>	<p>The Synovasure Alpha Defensin Lateral Flow Test Kit is a qualitative visually read immunochromatographic assay for the detection of human host response proteins, Alpha Defensins 1-3, in the synovial fluid of adults with a total joint replacement who are being evaluated for revision surgery.</p> <p>The Synovasure Alpha Defensin Lateral Flow Test Kit results are intended to be used in conjunction with other clinical and diagnostic findings as an aid in the diagnosis of periprosthetic joint infection (PJI). The Synovasure Alpha Defensin Lateral Flow Test Kit is not intended to identify the etiology or severity of a PJI.</p>	<p>The FebriDx® Bacterial/Non-bacterial Point-of-Care Assay is a qualitative visually read rapid immunoassay for the detection of human host response proteins, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from fingerstick blood. FebriDx is indicated for use in patients aged 12-64 who present to urgent care or emergency care settings for evaluation of acute respiratory infection who have had symptoms for less than 7 and within 3 days of fever onset.</p> <p>FebriDx test results are intended to be used in conjunction with other clinical and diagnostic findings as an aid in the</p>

	<b>DEN180032</b> Synovasure Alpha Defensin Lateral Flow Test Kit	<b>K230917</b> FebriDx® Bacterial/Non-Bacterial Point-of-Care Assay
		diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology. The assessment of whether a bacterial infection is present should always be based on consideration of all available information, and not based solely on the FebriDx test results. FebriDx test results are not intended to identify a specific pathogen or the severity of infection.
<b>Intended Use</b>	The Synovasure Alpha Defensin Control Kit is used in the Synovasure Alpha Defensin Lateral Flow Test Kit as assayed quality control samples to monitor performance and reliability of the Synovasure Alpha Defensin Lateral Flow Test Kit.	FebriDx External Controls are used in the FebriDx Test as assayed quality control samples to assess the performance and reliability of the FebriDx Test.
<b>External Controls</b>		
<b>Intended User</b>	Professional Use	Professional Use
<b>Equipment</b>	Visually read	Visually read
<b>Measurement</b>	Qualitative	Qualitative
<b>Device Format</b>	Single use disposable	Single use disposable
<b>Analyte</b>	One or more non-microbial analytes	One or more non-microbial analytes
<b>Measurand</b>	Human Alpha Defensins 1-3	MxA/CRP
<b>Test Type</b>	Lateral Flow immunochromatographic assay	Lateral Flow immunochromatographic assay
<b>Components</b>	Cassette with lateral flow test strip, separate tube, separate sample cup, and	All-in-one cassette with lateral flow test strip, safety lancet, blood collection



	<b>DEN180032</b> Synovasure Alpha Defensin Lateral Flow Test Kit	<b>K230917</b> FebriDx® Bacterial/Non-Bacterial Point-of-Care Assay
	separate buffer bottle.	and transfer tube, and buffer delivery system.
<b>Sample Type</b>	Synovial fluid	Fingerstick blood
<b>Sterility</b>	Test not provided sterile/aspiration device not included	Test not provided sterile/sterile lancet included
<b>Sample Volume</b>	15 µl	5 µl
<b>External Controls</b>	External positive and negative controls available	External positive and negative controls available
<b>Result time</b>	10 minutes (do not read after 20 minutes)	Minimum of 10 minutes (do not read after 1 hour)

**L. Standards/Guidance Documents Referenced:**

1. ISO 10993-1 Fifth edition 2018-08 Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
2. ISO 15223-1 Fourth Edition 2021-07 Medical Devices - Symbols To Be Used With Medical Device Labels, Labelling, And Information To Be Supplied - Part 1: General Requirements
3. CLSI EP07, Third Edition, Interference Testing in Clinical Chemistry
4. CLSI EP12-A2, User Protocol for Evaluation of Qualitative Test Performance
5. CLSI EP17-A2, Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures
6. CLSI EP18-A2, Risk Management Techniques to Identify and Control Laboratory Error Sources
7. CLSI EP25-A, Evaluation of Stability of In Vitro Diagnostic Reagents

**M. Performance Characteristics:**

**1. Analytical Performance:**

a. Precision/Reproducibility

The Precision & Reproducibility study was run at three (3) sites over five (5) days with two (2) medical professionals at each site who were representative of intended users, three (3) test kit lots and eighteen (18) blinded samples per run consisting of 3 blinded replicates of each sample. The evaluated panel members included C5 and C95 concentrations of both MxA and CRP as described below.

Sample	Sample Description
P1	C5 CRP / C95 MxA
P2	C95 CRP / C5 MxA
P3	C95 CRP/ C95 MxA
P4	C95 CRP / high (120 ng/mL) MxA
P5	High (150 ug/mL) CRP/ C95 MxA
P6	Negative (0 CRP/ 0 MxA)

The results demonstrate that the test is reproducible across the expected range of variability that would be encountered during normal expected use in the intended use setting. Results are summarized in the following table:

**Table 2. Reproducibility Study Results Final Interpretation – By Site**

Sample	% Agreement with Expected Results				95% CI
	Site 1	Site 2	Site 3	Overall	
P1	80% (24/30)	70% (21/30)	76.7% (23/30)	75.6% (68/90)	65.8-83.3%
P2	100% (30/30)	90% (27/30)	73.3% (22/30)	87.8% (79/90)	79.4-93.0%
P3	100%	90%	100%	96.7%	90.7-98.9%

	(30/30)	(27/30)	(30/30)	(87/90)	
P4	100% (30/30)	100% (30/30)	100% (30/30)	100% (90/90)	95.9-100%
P5	100% (30/30)	90% (27/30)	93.3% (28/30)	94.4% (85/90)	87.7-97.6%
P6	100% (30/30)	90% (27/30)	100% (30/30)	96.7% (87/90)	90.7-98.9%

**Table. 3 Reproducibility Study Results Final Interpretation – By Lot**

Sample	% Agreement with Expected Results		
	Lot 1	Lot 2	Lot 3
P1	75% (27/36)	80.5% (29/36)	66.7% (12/18)
P2	83.3% (30/36)	91.7% (33/36)	88.9% (16/18)
P3	100% (36/36)	100% (36/36)	83.3% (15/18)
P4	100% (36/36)	100% (36/36)	100% (18/18)
P5	91.7% (33/36)	94.4% (34/36)	100% (18/18)
P6	100% (36/36)	100% (36/36)	83.3% (15/18)

## b. Analytical Specificity

i. Cross-reactivity

Not applicable.

ii. Interfering Substances

The analytical specificity of the FebriDx test was determined by evaluating a series of samples that included MxA and CRP at the C95 concentration and negative levels in whole blood, spiked with interfering substances.

The following substances were evaluated on the FebriDx test and found to not interfere at the listed test concentrations:

**Table 4. Concentrations of substances found to not interfere on FebriDx**

Test Substance	Concentration
Acetaminophen	15.6 mg/dL
Acetylsalicylic acid	3 mg/dL
Alcohol	789 mg/dL
Azithromycin	1.11 mg/dL
Biotin	3500 ng/mL
Caffeine	10 mg/dL
Celecoxib	0.879 mg/dL
Cetirizine HCl	0.435 mg/dL
Conjugated Bilirubin	40 mg/dL
Dextromethorphan	1.56 ug/dL
Doxycycline	1.8 mg/dL
Furosemide	1.59 mg/dL
HAMA	524.6 ng/mL
Hemoglobin	1000 mg/dL
Ibuprofen	21.9 mg/dL
Imipenem	18 mg/dL
Levofloxacin	3.6 mg/dL
Loratadine	0.5 mg/dL
Nicotine	0.097 mg/dL
Oxymetazoline HCl	0.09 mg/dL
Phenylephrine	0.003 mg/dL
Prednisolone	0.120 mg/dL
Protein (total)	9 g/dL
Rheumatoid Factor (RF)	50 IU/mL*
Salmeterol	6.03 ug/dL
Tiotropium	4.80 ng/dL

Triglycerides	1500 mg/dL
Unconjugated Bilirubin	40 mg/dL
Vancomycin	12 mg/dL

The results of the FebriDx Interfering Substances Verification Study showed that the test substances did not interfere with the FebriDx test at the listed concentrations and acceptance criteria were met. Of note (\*), Rheumatoid Factor levels of up to 1000 IU/mL were evaluated and false negative/false positive results were identified. The interference effect disappeared at concentrations less than or equal to 50 IU/mL.

c. Detection Limit

The Limits of Detection (LoD) for the CRP and MxA assays on the FebriDx test were determined on two (2) lots of tests. A series of whole blood samples spiked with MxA and CRP analytes at concentrations spanning the assay range were blinded to test operators, tested, and read to determine the Limit of Detection (LoD) concentration (C95) and the C5:

**Table 5. Limit of Detection (LoD) Concentrations**

Lot	MxA (ng/mL)		CRP (ug/mL)	
	C5	C95 (LoD)	C5	C95 (LoD)
1	19	38	9	17
2	19	38	9	16

Based on the study results, the LoD (C95) was conservatively established as 40 ng/mL for the MxA assay and as 20 ug/mL for the CRP assay.

d. High Dose Hook Effect

The Hook Effect study assessed whether a hook effect exists on either the CRP and/or the MxA assays on the FebriDx test. MxA and CRP analytes were spiked into blood at the high concentrations shown in the table below and tested in replicates of ten (10) for each sample.

**Table 6. Hook Effect**

<b>Sample ID</b>	<b>MxA (ng/mL)</b>	<b>CRP (µg/mL)</b>
<b>1</b>	700	1000
<b>2</b>	600	800
<b>3</b>	500	600
<b>4</b>	400	500
<b>5</b>	200	250
<b>6</b>	100	125
<b>7</b>	50	62.5
<b>8</b>	0	0

These results indicate that there is no hook effect in the FebriDx test for the CRP assay up to a concentration of 1000 ug/mL and for the MxA assay up to a concentration of 700 ng/mL.

e. Assay cut-off

Not applicable.

f. Matrix Equivalency

Due to difficulties obtaining sufficient volumes of capillary blood, analytical studies for the FebriDx test were conducted with venous whole blood. To demonstrate equivalent analytical performance between venous whole blood and capillary fingerstick blood, a matrix equivalency study was conducted and similar LoDs for MxA and CRP were established for both matrices.

Venous and fingerstick blood samples procured from patients with a recent clinical fever were run on the FebriDx test and a reference ELISA method. Results of the comparisons for both MxA and CRP proteins showed agreement between the two sample matrices. This data is not intended to support a venous blood sample type.

g. Controls

i. Internal Controls

The FebriDx test has built-in procedural controls represented by a blue control line. For daily quality control, Lumos Diagnostics recommends documenting the procedural controls for the first sample tested each day.

ii. External Controls

External controls should be used to demonstrate that the reagents and assay perform properly. External controls (one positive and one negative) are optional and are not supplied with the FebriDx test kit (i.e. box of 25 devices). External controls should be used, consistent with good laboratory practices, to verify test performance. The manufacturer recommends external controls be run with every new lot, every new shipment, and with every first-time operator, but every testing site should follow their own protocols for running external controls.

h. Stability

Real time Stability Study

Real time stability was performed on three (3) production lots of the FebriDx test to support the recommended storage conditions of 4-25°C and demonstrated stability of 24 months.

Transport Stability Study

A transport stability study was performed on one (1) production lot of the FebriDx test. Results demonstrated that the FebriDx test is stable when exposed to expected conditions of transport.

In-Use Stability Study

In-use stability of one (1) lot of FebriDx tests was evaluated at various timepoints by a minimum of three (3) operators at each timepoint after being removed from the sealed packaging and being exposed to the environment (open pouch stability).

The study demonstrated in-use stability of up to 45 minutes after removal from sealed packaging.

#### External Quality Controls Shelf-Life Testing

Real time stability was performed on three (3) production lots of the FebriDx External Quality Controls to support the recommended storage conditions of 15-25°C and demonstrated stability of 10 months.



## 2. Clinical Performance:

A well-controlled, prospective, multi-center blinded clinical trial was conducted in the United States (U.S.) to evaluate the clinical performance of FebriDx. The study was conducted at 20 point-of-care (POC) testing sites that were representative of the intended user and setting. Patients who presented to urgent care or emergency care settings-for evaluation of acute respiratory infection (ARI) who had symptoms for less than 7 days and within 3 days of fever onset were screened for eligibility between October 2019-April 2021. Subjects were followed at study day 7 to identify participants who were admitted to the hospital for any reason. FebriDx was compared to a composite Clinical Reference Algorithm that incorporated pathogen detection testing (e.g., bacterial culture, multiplex PCR) as well as measures of host immune response. Physician adjudicators made a final qualitative diagnosis after review of all clinical and laboratory testing data.

### Comparator Method

Final diagnosis (Clinical Truth) was based on results of the Clinical Reference Algorithm (Comparator) in conjunction with adjudication by two independent expert reviewers, who were blinded to FebriDx results. Diagnostic accuracy was calculated by comparing the FebriDx result to the adjudicated Clinical Reference Algorithm. Primary analysis of diagnostic accuracy was based on positive percent agreement (PPA), negative percent agreement (NPA) and 95% confidence intervals (CI).

The following specimens were collected from each participant, on the day of FebriDx testing.

**Table 7. Clinical Comparator**

Comparator Testing	Visit 1
<i>FilmArray</i> ® Respiratory Panel PCR	x
Epstein Barre Virus (EBV), Herpes Simplex Virus (HSV), Cytomegalovirus qPCR	x
Bocavirus, <i>Fusobacterium necrophorum</i> , <i>Neisseria gonorrhoeae</i> PCR	x
SARS-CoV-2 PCR	x
Bacterial Culture	x
Hematology: Complete Blood Cell Count (CBC)	x
Antibody Testing: EBV IgM	x
B.R.A.H.M.S Procalcitonin	x

Study Demographics

Participants with symptoms for acute respiratory infection and a recent fever, were eligible for enrollment in the ARI cohort and participants without signs/symptoms of acute respiratory infection were eligible for enrollment in the asymptomatic control cohort. Demographics are summarized in the following table.

**Table 8. Demographics**

Characteristics	Asymptomatic Controls	ARI	Withdrawal after Consent	Overall
<b>Sex</b>				
Female	55.3% (94/170)	55.8% (290/520)	58.8% (10/17)	55.7% (394/707)
Male	44.7% (76/170)	44.2% (230/520)	41.2% (7/17)	44.3% (313/707)
<b>Age</b>				
N	170	520	18	708
Mean ± SD	43.5 ± 24.4	35.2 ± 17.7	31.1 ± 17.7	37.1 ± 19.8
Median	38.0	32.0	28.5	33.0
(IQR)	(19.0, 69.0)	(23.0, 48.0)	(24.0, 48.0)	(22.0, 50.0)
Min, Max	3, 87	1, 95	2, 66	1, 95
<b>Age Group</b>				
1-21 years	31.2% (53/170)	20.8% (108/520)	22.2% (4/18)	23.3% (165/708)
22-64 years	31.8% (54/170)	71.7% (373/520)	72.2% (13/18)	62.1% (440/708)
65+ years	37.1% (63/170)	7.5% (39/520)	5.6% (1/18)	14.5% (103/708)
<b>Race</b>				
American Indian	0	0.4% (2/520)	0	0.3% (2/708)
Asian	1.2% (2/170)	2.7% (14/520)	0	2.3% (16/708)
Black	17.1% (29/170)	21.2% (110/520)	33.3% (6/18)	20.5% (145/708)
Other	2.4% (4/170)	7.1% (37/520)	11.1% (2/18)	6.1% (43/708)
Pacific Islander	0	0.2% (1/520)	0	0.1% (1/708)
Unknown	0	0	5.6% (1/18)	0.1% (1/708)
White	79.4% (135/170)	68.5% (356/520)	50.0% (9/18)	70.6% (500/708)
<b>Ethnicity</b>				

Hispanic	12.4% (21/170)	18.7% (97/520)	5.6% (1/18)	16.8% (119/708)
Not Hispanic	87.6% (149/170)	80.6% (419/520)	88.9% (16/18)	82.5% (584/708)
Declined to answer	0	0.8% (4/520)	5.6% (1/18)	0.7% (5/708)

The study included 520 symptomatic participants with suspected acute respiratory infection who met inclusion and did not meet exclusion criteria. The cohort included male and female participants from each age group (pediatric, adult, elderly) with diverse ethnic backgrounds that were comparable to the 2020 U.S Census Bureau released demographic analysis.

All participants enrolled in the symptomatic cohort had multiple symptoms, with cough and sore throat being the most prevalent. All participants presented with a fever  $\geq 100.5^{\circ}\text{F}$  within 72 hours of enrollment, of which 31.9% were febrile at the time of enrollment.

External Controls

Positive and negative controls were performed every day of enrollment, with every new lot or shipment and with every first-time test operator. Prior to performing testing on study participants, 100% of positive and negative controls were read as positive and negative, respectively.

Analysis

Asymptomatic Controls

Of the total enrolled asymptomatic controls, FebriDx detected a bacterial infection in 3 cases where the adjudicated clinical reference algorithm classified the case as non-bacterial (NPA 98.1% (157/160), 95% CI (94.6%-99.4%)).

Acute Respiratory Infection (ARI) Cohort

Of the total enrolled participants with acute respiratory infection, 14.0% (73/520) were classified as having bacterial infection and 81.3% (423/520) were classified as having non-bacterial etiology by the comparator. FebriDx performance characteristics for bacterial infection are shown in the following table.

**Table 9. FebriDx Performance Characteristics for Bacterial Infection (Overall)**

Characteristic	Estimate	95% CI
PPA	93.2% (68 / 73)	84.9% - 97.0%
NPA	88.4% (374 / 423)	85.0% - 91.1%
PPV	58.1% (68 / 117)	49.1% - 66.7%
NPV	98.7% (374 / 379)	96.9% - 99.4%
LR+	8.0	6.1 - 10.5
LR-	0.08	0.03 - 0.2

FebriDx performance was analyzed as a subgroup of microbiologically confirmed infections. The performance for bacterial infection improved; PPA increased from 93.2% to 100%; NPA increased from 88.4% to 91.0%.

**Table 10. FebriDx Performance Characteristics for Bacterial Infection (Microbiologically Confirmed)**

Characteristic	Microbiologically Confirmed	Overall Performance
PPA (95% CI)	100% (33/33) (89%, 100%)	93.2% (68 / 73) (84.9%, 97.0%)
NPA (95% CI)	91.0% (263/289) (87%, 94%)	88.4% (374/ 423) (85.0%, 91.1%)
PPV (95% CI)	55.9% (33/59) (47%, 65%)	58.1% (68 / 117) (49.1%, 66.7%)
NPV (95% CI)	100% (263/263) (98.6%, 100%)	98.7% (374/ 379) (96.9%, 99.4%)
LR+ (95% CI)	11.1 (7.7, 16.0)	8.0 (6.1, 10.5)
LR- (95% CI)	0.0	0.08 (0.03, 0.2)

FebriDx performance was analyzed for different age groups (1-21 years, 22-64 years, 65+ years). A Fisher’s exact test was performed to evaluate the potential differences in age groups. The analysis showed there are no significant differences between the age groups for PPA. The DISRUPT study was not adequately powered to evaluate differences in performance among different age or demographic groups.

**Table 11. FebriDx Performance Characteristics (By Age)**

Characteristic	Estimate	95% CI
<b>1-21 years</b>		
<b>PPA</b>	100.0% (13 / 13)	77.2%, 100.0%
<b>NPA</b>	95.7% (88 / 92)	89.3%, 98.3%
<b>LR+</b>	23.0	8.8, 60.0
<b>LR-</b>	0.0	NA
<b>22-64 years</b>		
<b>PPA</b>	92.3% (48 / 52)	81.8%, 97.0%
<b>NPA</b>	86.7% (260 / 300)	82.4%, 90.1%
<b>LR+</b>	6.9	5.1, 9.3
<b>LR-</b>	0.1	0.03, 0.2
<b>65+ years</b>		
<b>PPA</b>	87.5% (7 / 8)	52.9%, 97.8%
<b>NPA</b>	83.9% (26 / 31)	67.4%, 92.9%
<b>LR+</b>	5.4	2.3, 12.6
<b>LR-</b>	0.1	0.02, 0.9

Participants were contacted on study day 7 to identify participants who were admitted to the hospital for any reason. By study day seven, 0.96% (5/520) of participants were admitted to the hospital (i.e., discharged home and returned to the hospital, requiring an overnight stay). Participants classified as ‘non-bacterial’ by the comparator at the initial study visit, and subsequently required hospitalization for pneumonia with objective evidence of a bacterial infection had the final classification changed to ‘bacterial’. None of the admitted patients met criteria for reclassification and there were no deaths, adverse events or unanticipated device effects that occurred during the study.

**N. Proposed Labeling:**

The labeling supports the determination of substantial equivalence for this device.

**O. Conclusions:**

The evidence provided in this Traditional 510(k) submission is sufficient to support a determination that the subject device is substantially equivalent to the legally marketed predicate device based on intended use, technology (basic design), performance, as well as the scientific rationale.